BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if erlotinib hydrochloride (OSI-774,
Tarceva®) can help to control NSCLC. The safety of this drug will also be studied, as well as
the drug's effect on different cells in the body and the participants' overall response.